RxDoctor Payments Data

Cara Elias

Psychiatric/Mental Health · Lyons, NYNPI 1154044337

Payments from drug & device makers

$3,778in general payments, 2019–2025

Across 120 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$877
  • AbbVie$852
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$712
  • Teva Pharmaceuticals USA, Inc.$385
  • Alkermes, Inc.$201
  • Axsome Therapeutics, Inc.$195
  • plus $556 from 11 others

What the payments were for

  • Food & beverage$3,778100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,778 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$9,184
Medicare patients
28
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine27$106,815
VraylarCariprazine Hcl53$86,296
Invega SustennaPaliperidone Palmitate23$82,640
AuvelityDextromethorphan Hbr/Bupropion15$15,613
Clozapine51$3,994
Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl11$2,935
Aripiprazole21$1,471
Haloperidol Decanoate23$1,256
Buspirone Hcl66$1,215
Olanzapine56$1,119
Bupropion XlBupropion Hcl32$1,097
Venlafaxine Hcl ErVenlafaxine Hcl46$800
Duloxetine Hcl22$486
Haloperidol31$441
Prazosin Hcl29$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$385$106,81527 claims
AbbVieVraylar$852$86,29653 claims
Johnson & JohnsonInvega Sustenna$877$82,64023 claims
Axsome Therapeutics, Inc.Auvelity$195$15,61315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Lyons

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →